With 6.1% CAGR Growth, Diabetes Drugs Market Is Expected to Grasp US$78,261.7 Mn by 2026

Diabetes is a chronic disease in which a person’s blood sugar or blood glucose gets too high. This glucose gets absorbed in the body through a hormone called insulin which is made in the pancreas. Insulin helps glucose enter the body’s cells, which, in turn, give the body energy to function. When the body does not make enough insulin or fails to make any insulin at all, a person becomes diabetic. The disease has no cure and can cause major health problems with age. Diabetes drugs are the medication that an affected person has to consume to regulate her glucose levels.

Rising Number of Type 2 Diabetes Cases to Fuel the Market

Diabetes has various forms and the most prevalent ones include Type 1 (body fails to make any insulin), Type 2 (body does not make enough insulin), gestational (develops in pregnant women), and monogenic (rare genetic form of diabetes). Type 2 diabetes is the most common form of diabetes as it develops during middle age. The global diabetes drugs market is expected to grow considerably as Type 2 diabetes becomes even more widespread. Increasing sedentary lifestyle, rising stress levels, lack of exercise leading to obesity, and unhealthy food habits are the factors cited for the growth of the market.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570

Undiagnosed Sections May Hinder Market Growth

The Centers for Disease Control and Prevention has revealed that around 7.2 mn people in the US remained undiagnosed in 2017. The global diabetes drugs market may see restrained growth as a result, since a large number of people remain untapped. However, as lifestyles get more sedentary and diagnostic methods get more advanced, the market is sure to gain momentum between 2018 and 2026 and register a CAGR of 6.1%.

By Geography:

· North America (U.S. and Canada)
· Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
· Latin America (Brazil, Mexico, and Rest of Latin America)
· Middle East and Africa (South Africa, GCC, and Rest of Middle East and Africa)

By Drug Class:

· Insulin
· DPP-4 Inhibitors
· GLP-1 Receptor Agonists
· SGLT2 Inhibitors

Get Sample PDF [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570

Rising Demand for Insulin Treatments to Surge the Market

Insulin provides the one of the most efficient treatment methods for diabetes. As a result, there is a growing demand for low-cost insulin treatments, especially to combat Type 2 diabetes. The rapidly rising insulin segment is, therefore, expected to boost the global diabetes drugs market during the forecast period. This has also encouraged private and public investments in research and development, which, in turn, will accelerate market growth. For example, recently, a rapid-acting, low-cost insulin called Lispro was launched in its generic form by Eli Lilly and Company in the US.
Market Competition Set to Intensify

Fortune Business Insights identifies some key players in the market which include Johnson and Johnson Services, Eli Lilly and Company, AstraZeneca, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Sanofi, and a few others.

TABLE OF CONTENT:
1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities

4. Key Insights

4.1 Prevalence of Diabetes – For Key Countries, 2018
4.2 Pipeline Analysis
4.3 Key Industry Developments Mergers, Acquisitions and Partnerships
4.4 Introduction of New Drugs/Approvals (by major players)
4.5 Overview of Regulatory Scenario of Key Countries/ Regions

5. Global Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast By Drug Class

5.2.1 Insulin
5.2.2 DPP-4 Inhibitors
5.2.3 GLP-1 Receptor Agonists
5.2.4 SGLT2 Inhibitors
5.2.5 Others

5.3. Market Analysis, Insights and Forecast By Diabetes Type

5.3.1 Diabetes 1
5.3.2 Diabetes 2

5.4 Market Analysis, Insights and Forecast By Route of Administration

5.4.1 Oral
5.4.2 Subcutaneous
5.4.3 Intravenous

5.5. Market Analysis, Insights and Forecast By Distribution Channel

5.5.1 Online pharmacies
5.5.2 Hospital Pharmacies
5.5.3 Retail Pharmacies

5.6. Market Analysis, Insights and Forecast By Region

5.6.1 North America
5.6.2 Europe
5.6.3 Asia Pacific
5.6.4 Latin America
5.6.5 Middle East and Africa

Speak to [email protected] https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetes-drugs-market-100570

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.